Definitive Contract 75A50121C00019
Award Date
2/1/21
Potential Completion Date
3/31/26
Potential Value
$52M
Awardee
Visby Medical, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
San Jose, CA 95134, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $34,714,763.00 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Detect Inc. to advance the development of a second-generation, multi-analyte molecular SARS-CoV-2 and influenza A/B test that has a reduced time to result and increased sensitivity for use at home or in a point-of-care setting. The contract is not set aside. The award references a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Program Phase I action contract to Visby Medical, Inc., a for-profit medical diagnostics manufacturer. The $140,000.00 firm-fixed-price contract, which was set aside for small businesses, is for the development of a rapid, accurate point-of-care diagnostic test under SBIR Topic 075. Visby Medical has received...
Visby Medical, Inc. was awarded a definitive contract valued at $9.5 million by the National Institutes of Health's National Heart Lung and Blood Institute to deliver a single-use, fully-integrated, rapid, automated reverse transcription polymerase chain reaction in vitro diagnostic test. The contract is associated with the Rapid Acceleration of Diagnostics program and will support Visby Medical's development and delivery of its rapid point-of-care COVID-19 diagnostic test. Work will be...
This is a $38,900,000.00 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Hologic, Inc. to ensure test availability for SARS-CoV-2 after the emergency authorization closes. The purpose is for Hologic to submit an in vitro diagnostic (IVD) assay for SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) by September 30, 2027. This contract was awarded under a Broad Agency Announcement (BAA)...
This is a $2,400,000.00 firm-fixed-price contract awarded by the U.S. Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Center for Industrial Base Expansion and Supply Chain (IBMSC) to Watmind USA, Inc., a small disadvantaged business. The contract is to provide 1,000,000 commercial off-the-shelf multi-antigen diagnostic test kits capable of detecting SARS-CoV-2 and Influenza A/B. The objective is to ensure the government is...
This federal contract award, valued at $2,040.00, was issued by the Medical Supply Chain division of the Defense agency to the prime contractor Cepheid, a for-profit manufacturer of molecular diagnostic solutions. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is May 17, 2024. The contract is for the provision of "XPCOV2/FLU/RSV-10" products, which are likely COVID-19, influenza, and respiratory syncytial virus (RSV) diagnostic...
This is a $24,860,014.00 firm-fixed-price contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Mesa Biotech Inc. for the development of an easy-to-use, low-cost molecular-based SARS-CoV-2 test. The contract is part of the Rapid Acceleration of Diagnostics (RADx) program, which aims to accelerate the development, validation, and commercialization of innovative COVID-19 testing technologies. The contract has a performance period ending on May 4, 2024,...
This is a delivery order awarded by the Medical Supply Chain, a component of the Defense Logistics Agency, to Cepheid, a for-profit manufacturer of molecular diagnostic solutions. The $4,080.00 firm fixed price contract is for the supply of XPCOV2/FLU/RSV-10 test kits, which can detect COVID-19, influenza, and respiratory syncytial virus. The contract has an ultimate completion date of December 4, 2024. Cepheid has received numerous federal contracts and grants related to its diagnostic...
This federal contract award, valued at $190,400.00, was issued by the Defense Logistics Agency Troop Support Medical to Cepheid, a for-profit manufacturer of molecular diagnostic solutions. The award is for the delivery of the "EUA XPERT XPRESS SARS-COV-2/FLU/RSV+" diagnostic test, which can detect SARS-CoV-2, influenza, and respiratory syncytial virus. The contract has a fixed-price with economic price adjustment pricing type and an ultimate completion date of August 14, 2024. This...
This federal contract award, valued at $4,080.00, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Cepheid, a for-profit manufacturer of molecular diagnostic solutions. The contract is a delivery order for XPCOV2/FLU/RSV-10 testing products, which include diagnostic tests for COVID-19, influenza, and respiratory syncytial virus. The contract has a firm fixed price pricing type and an ultimate completion date of March 19, 2024. This award does not have a...